Send your comments and tips to firstname.lastname@example.org
Beth Israel Deaconess Medical Ctr.
Boston Medical Center
Brigham and Women's Hospital
Cambridge Health Alliance
Caritas St. Elizabeth's Medical Ctr.
Children's Hospital Boston
Dana-Farber Cancer Institute
Joslin Diabetes Center
Mass. General Hospital
Mass. Health Law
New England Baptist Hospital
Short White Coat
Tufts-New England Medical Center
UMass Memorial Medical Center
University of Massachusetts
VA Medical Centers
A Healthy Blog
Running A Hospital
Nature Network Boston
SciBos - Corie Lok's blog
Dr. Flea's blog
Nurse at small
Your Child's Health Blog
Healthy Children blog
Other Globe Blogs
Elizabeth Cooney is a health reporter for the Worcester Telegram & Gazette.
Boston Globe Health and Science staff:
Karen Weintraub, Deputy Health and Science Editor, and Gideon Gil, Health and Science Editor.
Short White Coat blogger Ishani Ganguli
Wednesday, February 7, 2007
Today's Globe: overdose questions, Caritas debate, breast cancer relapse test, bleeding drug concerns
A doctor's role is questioned in a girl's fatal overdose from powerful prescription drugs fed to her by her parents. Prosecutors would not say whether Dr. Kayoko Kifuji of Tufts-New England Medical Center is a target of a criminal investigation, but have forwarded details from the case to state medical licensing regulators.
News that Ascension Health plans to absorb six Caritas Christi hospitals operated by the Archdiocese of Boston triggered a debate yesterday about the future of Catholic healthcare in the region. Mayor Thomas M. Menino expressed trepidation about the fate of two Boston hospitals in the chain, Caritas St. Elizabeth's Medical Center in Brighton and Caritas Carney in Dorchester.
The Food and Drug Administration yesterday approved a genetic test that, when conducted soon after a woman learns she has breast cancer, can predict the odds of the disease returning and worsening. The test, called MammaPrint, analyzes tissue from a breast tumor to gauge the activity of 70 key genes and determines the likelihood of the cancer's recurrence.
A drug widely used to prevent excessive bleeding during heart surgery appears to raise the risk of dying in the five years afterward by nearly 50 percent, an international study found. The researchers said replacing the drug -- aprotinin, sold by Bayer AG under the brand name Trasylol -- with other, less expensive medications for a year would prevent 10,000 deaths worldwide over the next five years.